Legal & General Group PLC Iveric Bio, Inc. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $219,733 - $331,861	-8,374 Reduced 6.88%	113,294 $4.46 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $1.3 Million - $1.71 Million	69,478 Added 133.13%	121,668 $2.96 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $264,392 - $367,297	15,336 Added 41.61%	52,190 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $23,020 - $45,526	2,449 Added 7.12%	36,854 $661,000
Q2 2022 Aug 22, 2022	BUY	$9.12 - $18.9 $41,869 - $86,769	4,591 Added 15.4%	34,405 $331,000

Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $20,849 - $28,880	1,716 Added 6.11%	29,814 $502,000
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $26,097 - $35,437	1,887 Added 7.2%	28,098 $470,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $100,804 - $249,515	14,258 Added 119.28%	26,211 $426,000
Q2 2021 Aug 12, 2021	BUY	$5.69 - $7.17 $5,069 - $6,388	891 Added 8.05%	11,953 $75,000
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $23,701 - $32,133	4,195 Added 61.09%	11,062 $76,000
Q3 2020 Nov 13, 2020	BUY	$4.01 - $6.29 $4,487 - $7,038	1,119 Added 19.47%	6,867 $39,000
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $17,588 - $37,936	5,748 New	5,748 $29,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.